Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) will host a webcast and conference call on May 14, 2026 at 8:30 a.m. ET to discuss first quarter 2026 financial results and provide a corporate update. A replay will be available on the company investor website about two hours after the call.
Analysts may register to participate in the Q&A; attendees are advised to join 15 minutes early.
Positive
- None.
Negative
- None.
News Market Reaction – IVVD
In the May 7 session, IVVD declined 2.05%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | +1.3% | Q3 2025 PEMGARDA growth, cash above $100M, pipeline progress for VYD2311. |
| Aug 14 | Q2 2025 earnings | Positive | -11.5% | Strong PEMGARDA revenue growth and positive VYD2311 Phase 1/2 data. |
| May 15 | Q1 2025 earnings | Positive | -15.8% | PEMGARDA revenue dip but improving net loss and sustained clinical progress. |
| Mar 20 | Q4/FY 2024 earnings | Positive | +2.6% | Q4 PEMGARDA growth to $13.8M and full-year revenue of $25.4M. |
| Feb 03 | Prelim Q4 2024 | Positive | +196.3% | Preliminary Q4 revenue strength and sharply reduced operating costs toward profitability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and financial updates have often produced large moves, with some strong positive reactions and a couple of notable selloffs despite positive fundamentals.
Recent earnings-related news for Invivyd shows significant volatility around fundamental updates. In Q4 2024 and full-year results, PEMGARDA revenue reached $13.8M for the quarter and $25.4M for 2024, with improving losses and a stated profitability goal, and the stock sometimes reacted positively. Other quarters, such as Q1 2025 and Q2 2025, combined revenue or pipeline positives with share price declines. The upcoming Q1 2026 call fits into this pattern of earnings events acting as key catalysts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 14, 2026 at 8:30 a.m. ET to discuss its first quarter 2026 financial results and provide a corporate update.
Interested parties can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
